The estimated Net Worth of Arthur S Leibowitz is at least $331 mil dollars as of 12 August 2022. Mr. Leibowitz owns over 3,000 units of Organogenesis stock worth over $181,386 and over the last 15 years he sold ORGO stock worth over $0. In addition, he makes $150,000 as Independent Director at Organogenesis.
Arthur has made over 3 trades of the Organogenesis stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 3,000 units of ORGO stock worth $14,280 on 12 August 2022.
The largest trade he's ever made was buying 6,943 units of Organogenesis stock on 17 November 2020 worth over $22,565. On average, Arthur trades about 996 units every 72 days since 2010. As of 12 August 2022 he still owns at least 70,854 units of Organogenesis stock.
You can see the complete history of Mr. Leibowitz stock trades at the bottom of the page.
Arthur S. Leibowitz serves as Independent Director of the Company. Mr. Leibowitz is a clinical professor at the Robert B. Willumstad School of Business at Adelphi University, where he teaches courses in accounting and auditing to both graduate and undergraduate students. Mr. Leibowitz began as an adjunct professor at Adelphi University in 2008, became a full-time lecturer in 2010 and was promoted to clinical professor in 2013. Mr. Leibowitz previously served as a member of the board of directors and the audit committee of Arotech Corporation from 2009 to 2014. Before joining Adelphi University, Mr. Leibowitz was an audit and business assurance partner at PricewaterhouseCoopers. During his twenty-seven years at PwC, Mr. Leibowitz served in a national leadership role for PwC’s retail industry group and was the portfolio audit partner for one of PwC’s leading private equity firm clients. Mr. Leibowitz is a certified public accountant in New York State and received a B.S. in accounting from Brooklyn College and a Masters of Accountancy from Stetson University.
As the Independent Director of Organogenesis, the total compensation of Arthur Leibowitz at Organogenesis is $150,000. There are 5 executives at Organogenesis getting paid more, with Gary S. Gillheeney Sr. having the highest compensation of $1,581,903.
Arthur Leibowitz is 66, he's been the Independent Director of Organogenesis since 2018. There are 3 older and 14 younger executives at Organogenesis. The oldest executive at Organogenesis Holdings Inc. is Alan Ades, 81, who is the Independent Director.
Arthur's mailing address filed with the SEC is C/O ORGANOGENESIS HOLDINGS INC., 85 DAN ROAD, CANTON, MA, 02021.
Over the last 5 years, insiders at Organogenesis have traded over $157,938,506 worth of Organogenesis stock and bought 15,146,267 units worth $65,732,558 . The most active insiders traders include Capital Managing Member Iv,..., Alan A.Erani Albert Erani D..., eGlenn H Wisdom Starr Nussdorf. On average, Organogenesis executives and independent directors trade stock every 24 days with the average trade being worth of $1,067,103. The most recent stock trade was executed by Patrick Bilbo on 28 March 2024, trading 152,250 units of ORGO stock currently worth $179,655.
Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic allograft wound covering and surgical barrier for application in the care of chronic and acute wounds or surgical implantation in spine, orthopedic, and sports medicine applications; Apligraf, a bioengineered bi-layered skin substitute for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft, a dermal substitute for the treatment of DFUs; NuShield, a dehydrated placental tissue wound covering and surgical barrier applied to the target tissue to support native healing; and PuraPly Antimicrobial, an antimicrobial barrier skin substitute to treat chronic and acute wounds. Its surgical and sports medicine products comprise NuCel, a surgically implanted allograft used primarily in spinal and orthopedic surgical applications; ReNu, a cryopreserved suspension used to support healing of soft tissues; and FiberOS and OCMP used as a bone void filler primarily in orthopedic and neurosurgical applications. The company's pipeline products include PuraPly XT and PuraPly MZ to treat chronic, acute, and open wounds; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; Novachor, a chorionic membrane wound covering; TransCyte, a bioengineered tissue for the treatment of partial thickness burns; and Gintuit, a bioengineered bi-layered living cellular tissue for the treatment of mucogingival conditions in adults. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales force and independent agencies. The company was founded in 1985 and is headquartered in Canton, Massachusetts.
Organogenesis executives and other stock owners filed with the SEC include: